BullFrog AI's VP to Present at Google's Cancer AI Symposium

GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) is excited to announce that its Vice President of Artificial Intelligence, Dr. Enrique García-Rivera, will be presenting at Google’s first-ever Cancer AI Symposium on October 30, 2024. This significant event will take place at the Boston Center for the Arts.

During the symposium, Dr. García-Rivera will discuss the innovative use of artificial intelligence in the realm of drug discovery and development undertaken by BullFrog AI. The presentation will specifically focus on the Company's unique bfLEAP™ platform. This platform integrates various biological data types—such as genomics, transcriptomics, and clinical data—with the aim of speeding up the drug development process.

A prominent feature of the presentation will be the application of bfLEAP™ in cancer research, where it helps identify complex biological patterns responsible for disease progression and treatment resistance. Furthermore, Dr. García-Rivera will highlight BullFrog AI's collaboration with the Lieber Institute for Brain Development, illustrating how bfLEAP™ is being effectively employed across diverse therapeutic areas, including cancer and neurological disorders like bipolar disorder.

Additionally, Dr. García-Rivera will present the revolutionary "AlgoLLM" system for gene prioritization. This advanced system redefines how researchers identify crucial targets for drug development by utilizing large language models. This state-of-the-art AI tool is vital for enhancing the discovery of actionable insights in various diseases, including neuropsychiatric disorders, and aligns perfectly with the Company’s goal of providing more tailored and effective treatments.

About BullFrog AI

BullFrog AI employs artificial intelligence and machine learning to revolutionize drug discovery and development. Through its partnerships with prominent research institutions, BullFrog AI utilizes causal AI alongside its proprietary bfLEAP™ platform to assess complex biological data. This strategy aims to optimize the development of therapeutics and decrease failure rates in clinical trials.

For additional information, please visit BullFrog AI at: bullfrogai.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements reflect our expectations and projections regarding future events, informed by currently available information. Forward-looking statements encompass future performance, including aspects such as financial results and business opportunities. They can typically be recognized by terms like "may," "should," "expects," and similar terms. It is critical to consider various factors when assessing these statements, as they may lead to outcomes that differ significantly from what is anticipated.

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
[email protected]

AI, Cancer, Research